OISTER optical and near-infrared monitoring observations of peculiar radio-loud active galactic nucleus SDSS J110006.07+442144.3

We present monitoring campaign observations at optical and near-infrared (NIR) wavelengths for a radio-loud active galactic nucleus (AGN) at z = 0.840, SDSS J110006.07+442144.3 (hereafter, J1100+4421), which was identified during a flare phase in late 2014 February. The campaigns consist of three intensive observing runs from the discovery to 2015 March, mostly within the scheme of the OISTER collaboration. Optical-NIR light curves and simultaneous spectral energy distributions (SEDs) are obtained. Our measurements show the strongest brightening in 2015 March. We found that the optical-NIR SEDs of J1100+4421 show an almost steady shape despite the large and rapid intranight variability. This constant SED shape is confirmed to extend to ∼5 μm in the observed frame using the archival WISE data. Given the lack of absorption lines and the steep power-law spectrum of α ν ∼ -1.4, where fνναν, synchrotron radiation by a relativistic jet with no or small contributions from the host galaxy and the accretion disk seems most plausible as an optical-NIR emission mechanism. The steep optical-NIR spectral shape and the large amplitude of variability are consistent with this object being a low ν peak jet-dominated AGN. In addition, sub-arcsecond resolution optical imaging data taken with Subaru Hyper Suprime-Cam does not show a clear extended component and the spatial scales are significantly smaller than the large extensions detected at radio wavelengths. The optical spectrum of a possible faint companion galaxy does not show any emission lines at the same redshift, and hence a merging hypothesis for this AGN-related activity is not supported by our observations. © The Author 2017. Published by Oxford University Press on behalf of the Astronomical Society of Japan. All rights reserved

Nucleolus organizer regions (NORs) in metastasizing pleomorphic adenoma

The metastasizing pleomorphic adenoma of the salivary glands is a rare variant of pleomorphic adenoma with a benign microscopical appearance, but malignant biological behaviour and production of metastasis. The histopathological study with the routine techniques is not enough for disclosing the nature of these tumors and they are most of the times underdiagnosed as benign. The correct diagnosis, almost always too late, is evident after several recurrences and the detection of metastatic foci. The number of nucleolar organizing regions (NORs) detected with the silver colloid method can be used in histopathology to determine the degree of cell activity. We report the findings in a case of metastasizing pleomorphic adenoma of the submandibular gland. This technique demonstrated to be useful for the diagnosis and characterization of the metabolism of these tumors.</p

Nucleolus organizer regions (NORs) in metastasizing pleomorphic adenoma

The metastasizing pleomorphic adenoma of the salivary glands is a rare variant of pleomorphic adenoma with a benign microscopical appearance, but malignant biological behaviour and production of metastasis. The histopathological study with the routine techniques is not enough for disclosing the nature of these tumors and they are most of the times underdiagnosed as benign. The correct diagnosis, almost always too late, is evident after several recurrences and the detection of metastatic foci. The number of nucleolar organizing regions (NORs) detected with the silver colloid method can be used in histopathology to determine the degree of cell activity. We report the findings in a case of metastasizing pleomorphic adenoma of the submandibular gland. This technique demonstrated to be useful for the diagnosis and characterization of the metabolism of these tumors.</p

Raman optical activity of tetra-alanine in the poly(l-proline) II type peptide conformation

The poly(l-proline) II (PPII) helix is considered to be a major conformation in disordered polypeptides and unfolded proteins in aqueous solution. The PPII conformation can be identified by using Raman optical activity (ROA), which measures the different intensities of right- and left-circularly polarized Raman scattered light from chiral molecules and provides information on stereochemistry associated with vibrational motions. In the present study, we used tetra-alanine (Ala 4 ) as a model system, since its central amide bond adopts the PPII conformation. The predominance of the PPII conformation was supported by 11 ns molecular dynamics (MD) simulations at 300 K. The MD snapshots were used for subsequent quantum mechanical/molecular mechanical (QM/MM) calculations to compute the Raman and ROA spectra. The present MD + QM/MM analysis leads to a good agreement between the observed and simulated spectra, allowing us to assign most of the spectral features including the ROA band near 1320 cm -1 , which has been used as a marker for the PPII conformation. This positive ROA band has three components. The lower frequency component near 1310 cm -1 arises from an internal peptide bond, whereas the higher frequency components around 1320-1335 cm -1 appear due to N- and C-terminal peptide groups. The MD + QM/MM calculations also reproduced the electronic circular dichroism spectra of Ala 4 . The present results provide a satisfactory framework for future investigations of unfolded/disordered proteins as well as peptides in solutions by chiral spectroscopic methods

High-dose Sequential Chemotherapy Versus A Less Intensive Regimen Followed By Peripheral Blood Autologous Hematopoietic Stem Cell Transplantation As Salvage Treatment In Relapsed And Refractory Hodgkin's Disease

Background and Objective. High-dose sequential chemotherapy (HDS) has been given to patients with Hodgkin's disease (HD) before autologous hematopoietic stem cell transplantation (HSCT), but its effectiveness has not been evaluated in comparison with less-aggressive regimens. In this study we compared HDS with a less-aggressive regimen as preparation to autologous HSCT in patients with HD. Design and Methods. Retrospective non-randomized comparison between patients receiving HDS (group 1, n=52) or a less-aggressive regimen (group 2, n=60). HDS consisted of the sequential administration of cyclophosphamide (7 g/m 2) and G-CSF (300 μg/day) with stem cell collection, methotrexate (8 g/m2) plus vincristine (1.4 mg/m2), and etoposide (2 g/m2). Group 2 patients received of 2 cycles of DHAP, followed by cyclophosphamide (1.5 g/m2) plus G-CSF and stem cell collection. Results. Group 1 patients were more likely to have stage IV (40% vs. 13%, p=0.001) and bulky disease (62% vs. 39%, p=0.02) at diagnosis. Disease status after chemotherapy improved in 59% in group 1 and 8% in group 2 (p&lt;0.001), mostly in patients with disease progression (DP): 50% in group 1 (4 CR and 12 PR) and none in group 2 (p&lt;0.001). Treatment-related toxicity occurred in 5/32 patients with DP in group 1, and 0/28 patients in group 2 (p=0.01). Overall survival was 49% in group 1 and 59% in group 2 (p=0.098). Interpretation and Conclusions. HDS seems to be useful in patients with DP, whereas patients with CR do well with less-intensive chemotherapy.278185Canellos, G.P., Anderson, J.R., Propert, K.J., Nissen, N., Cooper, M.R., Henderson, E.S., Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD (1992) N Engl J Med, 327, pp. 1478-1484Connors, J.M., State-of-the-art therapeutics: Hodgkin's lymphoma (2005) J Clin Oncol, 23, pp. 6400-6408Lister, T.A., Crowther, D., Sutcliffe, S.B., Glatstein, E., Canellos, G.P., Young, R.C., Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting (1989) J Clin Oncol, 7, pp. 1630-1636Hasenclever, D., Diehl, V., A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease (1998) N Engl J Med, 339, pp. 1506-1514Loureiro, M., Morais, J.C., Milito, C.B., Portugal, R.D., Pulcheri, W., Spector, N., Expression of Epstein-Barr virus in patients with Hodgkin's disease: Report of 64 cases from Rio de Janeiro, Brazil (2004) J Bras Patol Med Lab, 40, pp. 37-40de Souza, C.A., Vassallo, J., Lorand-Metze, I., Hodgkin's disease in Brazil: A clinicopathologic study (1997) Haematologica, 82, pp. 127-128Spector, N., Nucci, M., Oliveira De Morais, J.C., Maiolino, A., Portugal, R.D., Costa, M.A., Clinical factors predictive of bone marrow involvement in Hodgkin's disease (1997) Leuk Lymphoma, 26, pp. 171-176Canellos, G.P., Niedzwiecki, D., Long-term follow-up of Hodgkin's disease trial (2002) N Engl J Med, 346, pp. 1417-1418Spector, N., Costa, M.A., Morais, J.C., Biasoli, I., Solza, C., De Fatima, G.M., Intensified ABVP chemotherapy for the primary treatment of Hodgkin's disease (2002) Oncol Rep, 9, pp. 439-442Linch, D.C., Winfield, D., Goldstone, A.H., Moir, D., Hancock, B., McMillan, A., Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial (1993) Lancet, 341, pp. 1051-1054Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A.M., Haenel, M., Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial (2002) Lancet, 359, pp. 2065-2071Reece, D.E., Hematopoietic stem cell transplantation in Hodgkin disease (2002) Curr Opin Oncol, 14, pp. 165-170Baldissera, R.C., Aranha, J.F., Oliveira, G.B., Vigorito, A.C., Eid, K.A., Miranda, E.C., High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma (2002) Braz J Med Biol Res, 35, pp. 49-57Ferme, C., Mounier, N., Divine, M., Brice, P., Stamatoullas, A., Reman, O., Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial (2002) J Clin Oncol, 20, pp. 467-475Tarella, C., Cuttica, A., Vitolo, U., Liberati, M., Di, N.M., Cortelazzo, S., High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: A multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence (2003) Cancer, 97, pp. 2748-2759Josting, A., Rudolph, C., Mapara, M., Glossmann, J.P., Sienawski, M., Sieber, M., Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG) (2005) Ann Oncol, 16, pp. 116-123Josting, A., Autologous transplantation in relapsed and refractory Hodgkin's disease (2005) Eur J Haematol Suppl, 66, pp. 141-14

Chirality Effects in Jet-Cooled Cyclic Dipeptides

International audienc